Indaptus Therapeutics (NASDAQ:INDP) Upgraded at Wall Street Zen

Indaptus Therapeutics (NASDAQ:INDP) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Friday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Indaptus Therapeutics Stock Up 3.8%

INDP stock opened at $2.32 on Friday. The business’s fifty day moving average is $3.07 and its 200-day moving average is $6.75. The company has a market cap of $4.05 million, a P/E ratio of -0.06 and a beta of 1.00. Indaptus Therapeutics has a twelve month low of $1.65 and a twelve month high of $47.60.

Indaptus Therapeutics (NASDAQ:INDP) last issued its earnings results on Wednesday, November 12th. The company reported ($2.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.17) by $1.19. Research analysts anticipate that Indaptus Therapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.